Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

Bosutinib is a Src/Abl tyrosine kinase inhibitor indicated for adults with newly-diagnosed Philadelphia positive chronic myeloid leukemia or with resistant/intolerant disease. We report the final results of a phase I/II study of second-line bosutinib in chronic phase chronic myeloid leukemia patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambacorti-Passerini, Carlo, Cortes, Jorge E., Lipton, Jeff H., Kantarjian, Hagop M., Kim, Dong-Wook, Schafhausen, Philippe, Crescenzo, Rocco, Bardy-Bouxin, Nathalie, Shapiro, Mark, Noonan, Kay, Leip, Eric, DeAnnuntis, Liza, Brümmendorf, Tim H., Khoury, H. Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068045/
https://www.ncbi.nlm.nih.gov/pubmed/29773593
http://dx.doi.org/10.3324/haematol.2017.171249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6068045/
https://www.ncbi.nlm.nih.gov/pubmed/29773593
http://dx.doi.org/10.3324/haematol.2017.171249

Ejemplares similares